Clinical Guidelines

4DMT Completes Enrollment in Gene Therapy Trial for Wet AMD

Phase 3 4FRONT-1 study compares 4D-150, an investigational gene therapy, against aflibercept 2 mg in treatment-naïve patients

  • By

  • February 18, 2026

  • 2 min

Share

4D Molecular Therapeutics has completed enrollment for a phase 3 trial named 4FRONT-1, focusing on the investigational gene therapy 4D-150 for treating wet age-related macular degeneration. Conducted at over 100 sites in North America, the trial compares a single injection of 4D-150 with every-8-week injections of aflibercept (Eylea). The primary goal is to assess noninferiority in visual acuity over 52 weeks while evaluating treatment burden. Results from this trial are anticipated by the first half of 2027 and are part of a broader registrational program.

Original Source(s)

4DMT Completes Enrollment in Gene Therapy Trial for Wet AMD

Phase 3 4FRONT-1 study compares 4D-150, an investigational gene therapy, against aflibercept 2 mg in treatment-naïve patients

  • February 18, 2026

  • 2 min

Related Content

Can Diabetic Eye Testing Be Simplified?

Three-test models matched nine-test battery in classifying disease stages

Patterns of Spread in Ocular Melanoma

Study examines lymphatic and distant metastasis risk

A New Route for RGC Survival?

Vascularizing retinal organoids offers new possibilities for preserving retinal ganglion cells inside organoids

  • February 18, 2026

  • 2 min